Cytokinetics收涨逾25%！传诺华制药和阿斯利康有意收购_老虎社区_美港股上老虎

Cytokinetics收涨逾25%！传诺华制药和阿斯利康有意收购

智通财经网2023-12-22

12月22日，据知情人士透露，诺华制药和阿斯利康可能有意收购生物技术公司Cytokinetics。受此消息提振，该股周四收涨逾25%。知情人士表示，由于Cytokinetics预计将于本月公布其心脏病药物的后期数据，制药巨头们正处于观望状态。报道称，其他战略买家也在与这家生物技术公司接洽，等待数据公布。据了解，今年10月底有报道称，Cytokinetics在收到收购意向后，正在探索各种选择。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2393843953?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2023-12-22 08:21","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2393843953","market":"us","top_or_hot":-1,"title":"Cytokinetics收涨逾25%！传诺华制药和阿斯利康有意收购","media":"智通财经网","content":"<div>\n<p>12月22日，据知情人士透露，诺华制药和阿斯利康可能有意收购生物技术公司Cytokinetics。受此消息提振，该股周四收涨逾25%。知情人士表示，由于Cytokinetics预计将于本月公布其心脏病药物的后期数据，制药巨头们正处于观望状态。报道称，其他战略买家也在与这家生物技术公司接洽，等待数据公布。据了解，今年10月底有报道称，Cytokinetics在收到收购意向后，正在探索各种选择。...</p>\n\n<a href=\"https://www.zhitongcaijing.com/content/detail/1043923.html\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics收涨逾25%！传诺华制药和阿斯利康有意收购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics收涨逾25%！传诺华制药和阿斯利康有意收购\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-22 08:21 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/content/detail/1043923.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月22日，据知情人士透露，诺华制药和阿斯利康可能有意收购生物技术公司Cytokinetics。受此消息提振，该股周四收涨逾25%。知情人士表示，由于Cytokinetics预计将于本月公布其心脏病药物的后期数据，制药巨头们正处于观望状态。报道称，其他战略买家也在与这家生物技术公司接洽，等待数据公布。据了解，今年10月底有报道称，Cytokinetics在收到收购意向后，正在探索各种选择。...</p>\n\n<a href=\"https://www.zhitongcaijing.com/content/detail/1043923.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://www.zhitongcaijing.com/content/detail/1043923.html","article_id":"2393843953","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2393843953","pubTimestamp":1703204491,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据知情人士透露，诺华制药和阿斯利康可能有意收购生物技术公司Cytokinetics。受此消息提振，该股周四收涨约26%。知情人士表示，由于Cytokinetics预计将于本月公布其心脏病药物的后期数据，制药巨头们正处于观望状态。报道称，其他战略买家也在与这家生物技术公司接洽，等待数据公布。据了解，今年10月底有报道称，Cytokinetics在收到收购意向后，正在探索各种选择。另有消息称，Cytokinetics在获得收购兴趣后可能正在与一家投资银行合作。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","BK4578":"CAR-T","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4568":"美国抗疫概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4505":"高瓴资本持仓","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","CYTK":"Cytokinetics","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","NVS":"诺华","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","AZN":"阿斯利康","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Cytokinetics closed up more than 25%! Novartis Pharmaceuticals and AstraZeneca are interested in acquiring","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/0306211f448b4f7846cb38ae873d7b68","symbols_score_info":{"NVS":1,"CYTK":1,"AZN":1},"content_text":"12月22日，据知情人士透露，诺华制药和阿斯利康可能有意收购生物技术公司Cytokinetics。受此消息提振，该股周四收涨逾25%。知情人士表示，由于Cytokinetics预计将于本月公布其心脏病药物的后期数据，制药巨头们正处于观望状态。报道称，其他战略买家也在与这家生物技术公司接洽，等待数据公布。据了解，今年10月底有报道称，Cytokinetics在收到收购意向后，正在探索各种选择。近几个月来，该公司至少吸引了一家大型制药商的兴趣。另有消息称，Cytokinetics在获得收购兴趣后可能正在与一家投资银行合作。据称，这一兴趣来自一家瑞士公司。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}